Physician profile
Amber Syed
NPI 1225280795
$2,299.55
in general payments reported to CMS, 2019-2025
22 companies · $710 in 2025
The $710 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $103 · 2021: $227 · 2022: $287 · 2023: $442 · 2024: $531 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.43 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $326.53 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $144.73 | 2021-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $142.52 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $120.13 | 2024-2025 | |
| Amgen INC. | $108.66 | 2021-2025 | Evenity, Otezla, Repatha |
| Exact Sciences Corporation | $105.19 | 2023-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $101.38 | 2023-2025 | Accrufer |
| Dexcom, INC. | $93.55 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $87.32 | 2025 | |
| Abbott Laboratories | $77.81 | 2021-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $57.60 | 2023-2024 | Rexulti |
| Currax Pharmaceuticals LLC | $53.90 | 2022-2024 | Contrave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.89 | 2020-2022 | |
| Scynexis, INC. | $49.81 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $48.43 | 2021-2022 | |
| Gilead Sciences, INC. | $45.81 | 2020 | |
| Hologic Sales and Service, LLC | $25.58 | 2025 | Aptima |
| Astellas Pharma US INC | $21.20 | 2023 | Veozah |
| Amarin Pharma, INC. | $20.83 | 2020 | |
| Xeris Pharmaceuticals, INC. | $15.97 | 2025 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.